Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Fennec Pharmaceuticals	$9.70 -5.5%	$10.10	$6.30 ▼ $11.92	$278.09M	0.38	127,032 shs	249,137 shs
INMB INmune Bio	$8.43 -7.9%	$11.74	$6.50 ▼ $14.74	$164.94M	1.99	101,682 shs	148,236 shs
JNCE Jounce Therapeutics	$1.88 -2.6%	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	11.60 million shs
TSHA Taysha Gene Therapies	$2.45 -4.7%	$2.53	$0.50 ▼ $3.89	$481.57M	0.29	3.75 million shs	1.39 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Fennec Pharmaceuticals	-5.46%	-9.09%	-12.38%	-4.15%	+16.73%
INMB INmune Bio	-7.87%	-22.23%	-23.50%	-22.23%	+4.07%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	-1.05%
TSHA Taysha Gene Therapies	-4.85%	-21.97%	+15.02%	+71.33%	+215.32%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Fennec Pharmaceuticals	1.8604 of 5 stars	3.5	0.0	0.0	0.0	1.0	2.5	1.9
INMB INmune Bio	1.1246 of 5 stars	3.5	0.0	0.0	0.0	3.3	1.7	0.0
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	2.1885 of 5 stars	4.5	1.0	0.0	0.0	2.5	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Fennec Pharmaceuticals	3.00	Buy	$17.33	78.69% Upside
INMB INmune Bio	3.00	Buy	$16.00	89.80% Upside
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	3.00	Buy	$6.88	180.61% Upside

Current Analyst Ratings

Latest JNCE, TSHA, FENC, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
4/9/2024	TSHA Taysha Gene Therapies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
4/4/2024	FENC Fennec Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
3/21/2024	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
3/21/2024	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $7.00
3/20/2024	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/20/2024	TSHA Taysha Gene Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00
3/20/2024	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $7.00
3/18/2024	FENC Fennec Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
3/18/2024	FENC Fennec Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$16.00
2/29/2024	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Fennec Pharmaceuticals	$21.25M	12.37	N/A	N/A	($0.43) per share	-22.56
INMB INmune Bio	$160K	949.96	N/A	N/A	$2.07 per share	4.07
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53
TSHA Taysha Gene Therapies	$15.45M	29.66	N/A	N/A	$0.40 per share	6.13

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Fennec Pharmaceuticals	-$16.05M	-$0.61	N/A	13.86	N/A	-75.50%	N/A	-73.64%	5/9/2024 (Estimated)
INMB INmune Bio	-$30.01M	-$1.67	N/A	∞	N/A	-19,360.00%	-64.11%	-45.57%	5/1/2024 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A
TSHA Taysha Gene Therapies	-$111.57M	-$0.67	N/A	N/A	N/A	-722.06%	N/A	-55.72%	5/9/2024 (Estimated)

Latest JNCE, TSHA, FENC, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	FENC Fennec Pharmaceuticals	$0.02	-$0.10	-$0.12	-$0.10	$9.47 million	$9.74 million
3/19/2024	Q4 2023	TSHA Taysha Gene Therapies	N/A	$0.35	+$0.35	-$0.22	$4.75 million	$3.60 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Fennec Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Fennec Pharmaceuticals	N/A	3.56	3.27
INMB INmune Bio	N/A	2.16	2.16
JNCE Jounce Therapeutics	N/A	8.37	8.37
TSHA Taysha Gene Therapies	0.54	4.08	4.08

Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Fennec Pharmaceuticals	55.51%
INMB INmune Bio	12.72%
JNCE Jounce Therapeutics	80.66%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
FENC Fennec Pharmaceuticals	11.25%
INMB INmune Bio	36.10%
JNCE Jounce Therapeutics	6.92%
TSHA Taysha Gene Therapies	2.25%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Fennec Pharmaceuticals	N/A	27.10 million	24.06 million	Optionable
INMB INmune Bio	10	18.03 million	11.52 million	Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable
TSHA Taysha Gene Therapies	52	187.02 million	182.81 million	Optionable

JNCE, TSHA, FENC, and INMB Headlines

Source	Headline
	Certain Biotech Investors Get an Early Look at Results. Is That Fair? finance.yahoo.com - April 15 at 8:46 AM
	Vanguard Group Inc. Has $16.84 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) marketbeat.com - April 15 at 4:15 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5% americanbankingnews.com - April 14 at 6:08 AM
	Needham & Company LLC Reiterates "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) americanbankingnews.com - April 13 at 2:54 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading 3% Higher americanbankingnews.com - April 12 at 5:44 AM
	Impact and Outlook: Taysha Gene Therapies Stock Analysis markets.businessinsider.com - April 11 at 1:56 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLC marketbeat.com - April 11 at 8:32 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $2.68 americanbankingnews.com - April 11 at 5:40 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 3% marketbeat.com - April 10 at 12:36 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Now Covered by Analysts at Piper Sandler americanbankingnews.com - April 10 at 4:14 AM
	Taysha draws bullish view at Piper Sandler on lead asset msn.com - April 9 at 7:15 PM
	Buy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growth markets.businessinsider.com - April 9 at 9:14 AM
	Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts markets.businessinsider.com - April 9 at 9:14 AM
	Piper Sandler Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA) marketbeat.com - April 9 at 8:30 AM
	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - April 5 at 8:00 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.1% marketbeat.com - April 4 at 2:24 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71 marketbeat.com - April 3 at 1:36 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 2.6% marketbeat.com - March 26 at 12:59 PM
	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts marketbeat.com - March 26 at 5:01 AM
	Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript seekingalpha.com - March 21 at 6:44 PM
	Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Canaccord Genuity Group marketbeat.com - March 21 at 11:48 AM
	Taysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume After Analyst Upgrade marketbeat.com - March 21 at 10:28 AM
	Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts markets.businessinsider.com - March 21 at 8:29 AM
	Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - March 21 at 8:29 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Fennec Pharmaceuticals

NASDAQ:FENC

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

INmune Bio

NASDAQ:INMB

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Jounce Therapeutics

NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Taysha Gene Therapies

NASDAQ:TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial